396 related articles for article (PubMed ID: 18777156)
1. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
[TBL] [Abstract][Full Text] [Related]
2. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Rosak C; Hofmann U; Paulwitz O
Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
[TBL] [Abstract][Full Text] [Related]
3. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
[TBL] [Abstract][Full Text] [Related]
4. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
5. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
6. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
7. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes.
Gallagher A; Home PD
Diabetes Res Clin Pract; 2005 Mar; 67(3):196-203. PubMed ID: 15713351
[TBL] [Abstract][Full Text] [Related]
8. Treatment with insulin glargine does not suppress serum IGF-1.
Slawik M; Schories M; Busse Grawitz A; Reincke M; Petersen KG
Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
[TBL] [Abstract][Full Text] [Related]
9. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
Pala L; Mannucci E; Dicembrini I; Rotella CM
Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
[TBL] [Abstract][Full Text] [Related]
10. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D
Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
[TBL] [Abstract][Full Text] [Related]
11. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
[TBL] [Abstract][Full Text] [Related]
12. Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity.
Wu MK; Huang CY; Liou YJ; Wang CK; Lee SD
Int J Obes (Lond); 2008 Mar; 32(3):436-42. PubMed ID: 17955031
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
[TBL] [Abstract][Full Text] [Related]
14. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.
Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975
[TBL] [Abstract][Full Text] [Related]
16. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
Shapiro MS; Abrams Z; Lieberman N
Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
[TBL] [Abstract][Full Text] [Related]
18. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.
Warren ML; Conway MJ; Klaff LJ; Rosenstock J; Allen E
Diabetes Res Clin Pract; 2004 Oct; 66(1):23-9. PubMed ID: 15364158
[TBL] [Abstract][Full Text] [Related]
19. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
[TBL] [Abstract][Full Text] [Related]
20. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
Bi YF; Zhao LB; Li XY; Wang WQ; Sun SY; Chen YH; Hong J; Su TW; Liu JM; Ning G
Chin Med J (Engl); 2007 Oct; 120(19):1700-3. PubMed ID: 17935674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
